Midatech Pharma Plc ROCE
What is the ROCE of Midatech Pharma Plc?
The ROCE of Midatech Pharma Plc is 0.00%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on LSE compared to Midatech Pharma Plc
What does Midatech Pharma Plc do?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Companies with roce similar to Midatech Pharma Plc
- Omega Alpha Spac has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- Elemental Royalties Ltd has ROCE of -0.01%
- Auburn National Bancorp has ROCE of -0.01%
- Galaxy Digital has ROCE of -0.01%
- The Gap has ROCE of -0.01%
- Midatech Pharma Plc has ROCE of 0.00%
- Tejon Ranch Co has ROCE of 0.01%
- Glen Burnie Bancorp has ROCE of 0.02%
- MSP Steel & Power has ROCE of 0.02%
- TTL Beteiligungs- und Grundbesitz-AG has ROCE of 0.03%
- First Foundation Inc has ROCE of 0.03%
- FirstMark Horizon Acquisition has ROCE of 0.03%